Chronic myeloid leukaemia: trials for referral
190 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Chronic myeloid leukaemia·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
190 trials shown
Phase 11 site
RecruitingNorway
NCT07651878
Vididencel in CML-CP Patients With MRD
Mendus
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07468916
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 142 sites
By invitation onlyAustralia, Belgium, Denmark, Spain, France, United Kingdom
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07914556
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Mabwell (Shanghai) Bioscience Co., Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingUnited States
NCT07604233
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06629584
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07909733
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
University of Wisconsin, Madison
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06236724
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/24 sites
RecruitingUnited States
NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07758218
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
University of Wisconsin, Madison
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07254793
Prophylactic DLI-X for Leukemia Relapse After HCT
University of Arizona
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07905183
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
Enliven Therapeutics
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07020533
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingChina
NCT07885293
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07379125
Therapeutic RSK1 Targeting in Myeloid Malignancies
Washington University School of Medicine
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT06088888
TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
Shenzhen TargetRx Co., Ltd.
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT06543381
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 1/253 sites
RecruitingAustralia, Germany, Spain, France, United Kingdom, Italy
NCT06163430
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06691217
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Massachusetts General Hospital
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 232 sites
RecruitingAustralia, Brazil, Canada, China, Germany, Spain
NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis Pharmaceuticals
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07269470
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT07128381
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “JAKi-naive cohort (Cohort D): patients with newly diagnosed and treatment naive MF with intermediate .1 risk by DIPSS-plus (Appendix 2)”
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 1/223 sites
RecruitingBelgium, Spain, France, United Kingdom, Italy, Netherlands
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07582172
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
Registry updated 8 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT03896269
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT04140487
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States101 open trials
- France30 open trials
- China22 open trials
- Italy20 open trials
- Germany19 open trials
- Spain18 open trials
- Poland13 open trials
- United Kingdom12 open trials
- South Korea11 open trials
- Australia10 open trials
- Netherlands10 open trials
- Canada10 open trials
- Belgium8 open trials
- Japan7 open trials
- Hungary7 open trials
- Russia7 open trials
- Denmark6 open trials
- Greece5 open trials
- Türkiye4 open trials
- Austria4 open trials
- Taiwan3 open trials
- Brazil3 open trials
- Sweden3 open trials
- Czechia3 open trials
- Slovakia3 open trials
- Norway2 open trials
- Ukraine2 open trials
- Israel2 open trials
- New Zealand2 open trials
- Thailand2 open trials
- Bulgaria2 open trials
- Romania2 open trials
- Lebanon2 open trials
- Hong Kong2 open trials
- Moldova1 open trial
- Georgia1 open trial
- Switzerland1 open trial
- India1 open trial
- Singapore1 open trial
- Armenia1 open trial
- Finland1 open trial
- Portugal1 open trial
- Malaysia1 open trial
- Argentina1 open trial
- Vietnam1 open trial
- Saudi Arabia1 open trial
- Egypt1 open trial
- Belarus1 open trial
- Croatia1 open trial
- Chile1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Catania, Italy
3 trials · 6 publications · ROR
Eulji University Uijeongbu Eulji Medical Center
Uijeongbu-si, South Korea
2 trials · 14 publications · ROR
Federal Almazov North-West Medical Research Centre
St Petersburg, Russia
1 trial · 13 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
11 trials · 8 publications · ROR
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
1 trial · 6 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574 · Phase 2 · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07082452 · Phase 3 · Spain, France
Source: ClinicalTrials.govOpened for recruitment
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936 · Phase 2 · Spain, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05428969 · Phase 1/2 · Finland, United Kingdom, United States
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 4
NCT04877522 · Phase 4 · Argentina, Austria, Bulgaria, Brazil, Canada, China
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 2/3
NCT04256317 · Phase 2/3 · Canada, Czechia, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04147533 · Phase 2 · Czechia
Source: ClinicalTrials.govOpened for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
NCT03895671 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
NCT03831776 · Phase 2 · Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT00777036 · Phase 2 · Argentina, Australia, Brazil, Canada, Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936 · Phase 2 · Spain, Italy
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Not yet recruiting
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574 · Phase 2 · Germany
Source: ClinicalTrials.govClosed for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.govClosed for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govStopped early
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
NCT02530034 · Phase 1 · United States
Source: ClinicalTrials.govPhase changed: No phase → Phase 1
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.gov
Show more
New in the registry
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
NCT07914556 · Phase 1 · China
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 15 Oct 2026
Stopped early15 participants
NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given: FDA Clinical Hold
Phase 2Ended 8 Sept 2026
Completed93 participants
NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Phase 2Ended 17 Jul 2026
Phase 2Ended 11 Jun 2026
Withdrawn before start0 participants
NCT06597734
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Reason given: PI request
Phase 2Ended 2 Jun 2026
Phase 2Ended 31 May 2026
Phase 1/2Ended 29 May 2026
Stopped early34 participants
NCT04550442
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Reason given: \<75% participation
No phaseEnded 26 May 2026
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 4Ended 5 May 2026
Completed450 participants
NCT02602314
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.
Phase 4Ended 20 Apr 2026
Phase 4Ended 18 Mar 2026
Phase 2Ended 5 Mar 2026
Stopped early235 participants
NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Reason given: \<75% participation
Phase 3Ended 25 Feb 2026
Phase 2Ended 5 Feb 2026
Completed17 participants
2024-518971-76-00
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia
Phase 1/2Ended 3 Feb 2026
Stopped early51 participants
NCT04160052
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Reason given: \<75% participation
Phase 2Ended 2 Feb 2026
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 31 Dec 2025
Completed34 participants
NCT04160546
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
Phase 1/2Ended Dec 2025
Withdrawn before start0 participants
NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given: PI has left IU with no plan to initiate study at IU
Show more
Phase 2Ended 31 Dec 2025
Completed32 participants
NCT03895671
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
Phase 1Ended 19 Dec 2025
Phase 1/2Ended Nov 2025
Withdrawn before start0 participants
NCT05246384
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Reason given: Change in development plan
Phase 2Ended 27 Nov 2025
Completed33 participants
2023-509092-16-00
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
Phase 1Ended 24 Oct 2025
Stopped early25 participants
NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Reason given: Slow enrolment
Phase 3Ended 17 Oct 2025
Completed21 participants
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Phase 2Ended 15 Oct 2025
Completed170 participants
2024-516122-66-00
A study of full treatment-free remission in patients with chronic myeloid leukemia
Phase 1/2Ended 13 Oct 2025
Completed54 participants
NCT06563804
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
No phaseEnded 15 Sept 2025
Completed105 participants
NCT05682924
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Phase 1Ended 25 Aug 2025
Completed153 participants
NCT04609826
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 4Ended 11 Aug 2025
Completed136 participants
2024-516511-24-00
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study
Phase 1Ended 5 Aug 2025
Completed13 participants
NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Phase 1Ended 1 Aug 2025
Completed50 participants
NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
No phaseEnded Jul 2025
Completed13 participants
NCT01316250
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
No phaseEnded Jul 2025
Completed10 participants
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Phase 1Ended Jul 2025
Withdrawn before start0 participants
NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given: Medigene transfered all rights to a new Sponsor
Phase 4Ended 30 Jul 2025
Phase 3Ended 2 Jul 2025
Stopped early8 participants
NCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Reason given: Insufficient patient accrual
Phase 2Ended 19 Jun 2025
Completed12 participants
NCT05024994
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
- Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers. · Blood cancer discovery, 2026
Phase 2Ended 15 May 2025
Phase 2Ended 3 May 2025
Stopped early150 participants
NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given: Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.
Phase 2Ended 1 May 2025
Phase 1Ended 24 Apr 2025
Phase 2Ended 23 Apr 2025
Phase 2Ended 24 Mar 2025
Completed78 participants
NCT02988466
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2Ended 17 Mar 2025
Stopped early7 participants
NCT04216563
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
Reason given: 75% \< Participants, Administrativley Complete
Phase 2Ended 14 Mar 2025
Completed150 participants
NCT00254423
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Phase 1Ended 5 Mar 2025
Completed30 participants
NCT05153330
A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219
Phase 1/2Ended 3 Mar 2025
Completed17 participants
NCT05282459
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Phase 2Ended 26 Feb 2025
Phase 1Ended 20 Feb 2025
Phase 3Ended 7 Feb 2025
Completed125 participants
NCT02730299
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Phase 1Ended 5 Feb 2025
Completed6 participants
NCT04512105
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Phase 1Ended 31 Jan 2025
Stopped early28 participants
NCT05787496
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Reason given: As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.
Phase 1Ended 31 Jan 2025
Completed67 participants
NCT04372433
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
Phase 2Ended 29 Jan 2025
Completed163 participants
NCT01698905
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Phase 2Ended 28 Jan 2025
Withdrawn before start0 participants
NCT04264806
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Reason given: The cusatuzumab MDS strategy is under revision
Phase 2Ended 27 Jan 2025
Phase 2Ended 23 Jan 2025
Completed215 participants
NCT01784068
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
No phaseEnded 21 Jan 2025
Completed1480 participants
NCT07374120
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
Not medical advice. fetched 10 Nov 2026